The 28 references in paper O. Leplina Yu., M. Tihonova A., Yu. Kozlov P., V. Stupak V., S. Nikonov D., A. Ostanin A., E. Chernykh R., О. Леплина Ю., М. Тихонова А., Ю. Козлов П., В. Ступак В., С. Никонов Д., А. Останин А., Е. Черных Р. (2014) “ЧАСТИЧНО–ЗРЕЛЫЕ ДЕНДРИТНЫЕ КЛЕТКИ КАК ПОТЕНЦИАЛЬНАЯ ОСНОВА ДЛЯ ИНДУКЦИИ ПРОТИВООПУХОЛЕВОГО ОТВЕТА У БОЛЬНЫХ ЗЛОКАЧЕСТВЕННЫМИ ГЛИОМАМИ // SEMI–MATURE DENDRITIC CELLS AS A POTENTIAL BASIS FOR THE INDUCTION OF ANTI–TUMOR RESPONSE IN PATIENTS WITH MALIGNANT GLIOMAS” / spz:neicon:mimmun:y:2005:i:4:p:365-374

1
Лозовой В.П., Кожевников В.С. Методы оценки клеточных эффекторных функций гиперчувствительности замедленного типа // Методические рекомендации. – Москва, 1990. – С.1-10.
(check this in PDF content)
2
Останин А.А., Центнер М.И., Хонина Н.А., Леплина О.Ю., Шевела Е.Я., Никонов С.Д., Ступак В.В., Черных Е.Р. Антигенспецифическая иммунотерапия в комплексном лечении больных со злокачественными опухолями головного мозга // Вопр. онкологии.- 2003.- Т. 49, No 2.- С. 170-175.
(check this in PDF content)
3
Хонина Н.А., Центнер М.И., Леплина О.Ю., Тихонова М.А., Ступак В.В., Никонов С.Д., Черных Е.Р., Останин А.А. Характеристика и механизмы иммунных нарушений у больных со злокачественными опухолями головного мозга // Вопр. онкологии.- 2002.- Т. 48, No 2.- С. 196-201.
(check this in PDF content)
4
Черных Е.Р., Леплина О.Ю., Останин А.А., Никонов С.Д., Ступак В.В., Козлов Ю.П. Способ иммунотерапии злокачественных опухолей головного мозга // Заявка на изобретение No 2004100550/ 14 (00155) приоритет от 05.01.2004 г.
(check this in PDF content)
5
Черных Е.Р., Ступак В.В., Центнер М. И., Хонина Н. А., Леплина О. Ю., Тихонова М.А., Никонов С. Д., Останин А. А. Комбинированная иммунотерапия в лечении злокачественных опухолей головного мозга // Мед. иммунология.- 2002.- Т. 4, No 4/5.- С.583-592.
(check this in PDF content)
6
Adams M., Navaba H., Jasani B., Man S., Fiander A., Evans A.S., Donninger C., Mason M. D. Dendritic cell based therapy for cervical cancer – use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly // Vaccine.– 2003. – Vol.21. – P.787-790.
(check this in PDF content)
7
Akasaki Y., Kikuchi T., Homma S. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model // J. Immunother.- 2001.-Vol. 24.- P. 106-113.
(check this in PDF content)
8
Asavaroengchai W., Kotera Y., Mule J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery // Proc. Natl. Acad. Sci. USA. 2002.– Vol. 99. – P. 931-936.
(check this in PDF content)
9
Baar J. Clinical applications of dendritic cell cancer vaccines // Oncologist.– 1999. – Vol. 4. – P. 140-144.
(check this in PDF content)
10
Bjork P. Development of dendritic cells and their use in tumor therapy // Clin. Immunol.– 1999. – Vol. 92, N. 2. – P. 119-127.
(check this in PDF content)
11
Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy // Annu. Rev. Immunol.- 2000.Vol. 18.- P. 245-273.
(check this in PDF content)
12
Kikuchi T., Akasaki Y., Irie M.. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells //Cancer Immunol Immunother.- 2001.-Vol.50.-P.337-344.
(check this in PDF content)
13
Liau L.M., Black K.L., Prins R.M. Treatment of intracranial gliomas with bone-marrow-derived dendritic cells pulsed with tumor antigens. // J.Neurosurg.-1999.-Vol.90.-P.1115-1124.
(check this in PDF content)
14
Lipcomb M., Masten B.J. Dendritic cells – immune regulators in health and disease // Physiol. Rev.– 2002. – Vol.82. – P.97-130.
(check this in PDF content)
15
Mcllroy D., Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy – maturation state does have clinical impact // Cancer Immunol. Immunother. – 2003.- Vol. 52. – P. 583-591.
(check this in PDF content)
16
Murphy G., Tjoa B., Simmons S., Jarisch J., Bowes V., Ragde H., Elgamal A., Kenny G., Cobb O., Ireton R., Troychak M., Salgaller M., Boynton A. Infusion of dendritic cells pulsed with HLA-A2-spesific prostate-specific membrane antigen peptides – a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease // Prostate.- 1999. – Vol. 38. – P. 73-78.
(check this in PDF content)
17
Orada I., Tahara I., Shurin M., Attanucci J., Giezeman –Smits K., Fellows W., Lotze M., Chambers W., Bozik M. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide el icit effective anti-tumor immunity against intracranial neoplasms // J. Neurooncol.- 1998. – Vol. 38. – P. 233239.
(check this in PDF content)
18
Parlato S., Santini S., Lapenta C., Di Pucchio T., Logozzi M., Spada M., Giammarioly A., Malorni W., Fais S., Bellardelli F. Expression of CCR-7, MIP3b, and Th1 chemokines in type I IFN-induced monocyte-derived dendritic cells – importance for the rapid acquisition of potent migratory and functional activities // Blood.- 2001.– Vol.98. – P. 3022-3029.
(check this in PDF content)
19
Pickl W., Majdic O., Kohl P., Stockl J., Reidl E., Scheinecker C., Bello-Fernandez C., Knapp W. Molecular and functional characteristics of dendritic cells generated from highly purified CD 14 peripheral blood monocytes // J. Immunol.- 1996.– Vol. 157. – P. 3850-3859.
(check this in PDF content)
20
Piemonti L., Monti P., Allavena P., Leone B.E., Caputo A., Carlo V.D. Glucocorticoids increase the endocytic activity of human dendritic cells // Int. Immunol. – 2002. – Vol. 11.– N. 9. – P. 1519-1526.
(check this in PDF content)
21
Santini S., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., Bellardelli F. Type I Interferon as a powerful adjuvant for monocyte-derived dendritic cells development and activity in vitro and in HU-PBL-SCID mice // J. Exp. Med.– 2000.-Vol. 191. – P. 1777-1788.
(check this in PDF content)
22
Schuler-Thurner B., Schultz E., Berger T., Weinlich G., Ebner S., Woel P., Bender A., Feuerstain B., Fritsch P., Romani N., Schuler G. Rapid induction of tumor-specific type I T-helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells // J. Exp. Med.– 2002.- Vol. 195.– P. 1279-1288.
(check this in PDF content)
23
Steinman R.M., Dodhapkar M. Active immunization against cancer with dendritic cells: the near future // Int. J. Cancer.- 2001.- Vol. 94.- P. 459–473.
(check this in PDF content)
24
Thurner B., Roder C., Dieckmann D., Heuer M., Kruse M., Glaser A., Keikavoussi P., Kampgen E., Bender A., Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical applications // J. Immunol. Meth. – 1999. – Vol. 223. – P. 1-15.
(check this in PDF content)
25
Valone F.H., Small E., MacKenzie M., Burch P., Lacy M., Peshwa M.V., Laus R. Dendritic cellbased treatment of cancer: closing in on a cellular therapy // Cancer J.- 2001.- Vol. 1/2.- P. 53-61.
(check this in PDF content)
26
Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial / / Br. J. Cancer.- 2003.- Vol. 89.- P. 1172-1179.
(check this in PDF content)
27
Yamanaka R., Yajima N., Abe T., Tsuchiya N., Homma J., Narita M., Takahashi M., Tanaka R. Dendritic cell-based glioma immunotherapy // Int. J. Oncol .- 2003.- Vol. 23.-P. 5-15.
(check this in PDF content)
28
Yu J.S., Wheller C.J., Zelter P., Ying H., Finger D., Lee P.K., Yong W.H., Incardona F., Thompson R., Riedinger M., Zhang W., Prins R., Black K. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicit systemic cytotoxity
(check this in PDF content)